Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Celadon Pharmaceuticals PLC

Healthcare GB CEL

NoneGBX
0.00(0%)

Last update at 2025-09-05T16:00:03.377830Z

Day Range

--
LowHigh

52 Week Range

48.00189.00
LowHigh

Fundamentals

  • Previous Close 13.40
  • Market Cap73.84M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-6.95800M
  • Revenue TTM0.02M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.06600M
  • Diluted EPS TTM-0.13

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2020-08-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2020-08-31
Income before tax -18.11800M -4.79600M -1.05979M -
Minority interest 0.41M 0.15M - -
Net income -17.41100M -4.78300M -1.39895M -
Selling general administrative - - 0.26M -
Selling and marketing expenses - - - -
Gross profit -0.06600M -0.01000M 0.00000M -
Reconciled depreciation 0.47M 0.32M 0.16M -
Ebit -5.38100M -2.71300M -0.72065M -
Ebitda -12.43900M -2.39400M -0.55979M -
Depreciation and amortization -7.05800M 0.32M 0.16M -
Non operating income net other - - - -
Operating income -5.38100M -2.71300M -0.72065M -
Other operating expenses 12.94M 2.71M 0.72M 0.00073M
Interest expense 4.04M 0.65M 0.34M -
Tax provision -0.70700M -0.01300M 0.00000M -
Interest income 0.01M 0.00000M 0.00001M -
Net interest income -4.02800M -0.64600M -0.33915M -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -0.70700M -0.01300M 0.34M -
Total revenue 0.02M 0.00200M 0.00000M -
Total operating expenses 12.85M 2.70M 0.72M -
Cost of revenue 0.09M 0.01M 0.00000M -
Total other income expense net -12.73700M -2.08300M -0.33915M -
Discontinued operations - - - -
Net income from continuing ops -17.41100M -4.78300M -1.05979M -
Net income applicable to common shares -17.00600M -0.21927M -1.05979M -1.05979M
Preferred stock and other adjustments - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 13.25M - 3.85M 2.49M
Intangible assets 0.35M - - -
Earning assets - - - -
Other current assets - - 0.44M 0.00111M
Total liab 6.21M - 3.75M 2.60M
Total stockholder equity 7.67M - 0.10M -0.11347M
Deferred long term liab - - - -
Other current liab 0.59M 0.00305M -0.00000M 0.07M
Common stock 0.62M 0.08M 0.00031M 0.00030M
Capital stock 0.62M - 0.00031M 0.00030M
Retained earnings -22.80700M -1.08620M -1.17357M -0.11377M
Other liab 0.45M 0.02M 0.00000M -
Good will 0.08M - 0.08M 0.00000M
Other assets - - - -
Cash 5.06M - 0.30M 0.00149M
Cash and equivalents - - - -
Total current liabilities 1.20M 0.18M 0.83M 0.07M
Current deferred revenue - - 0.57M -
Net debt -0.42900M - 2.62M 2.53M
Short term debt 0.07M - 0.00667M -
Short long term debt 0.01000M - 0.00667M -
Short long term debt total 4.63M - 2.92M 2.54M
Other stockholder equity 29.86M 0.05M 1.27M -
Property plant equipment 6.28M - 3.03M -
Total current assets 6.33M 6.61M 0.74M 0.00260M
Long term investments - - - -
Net tangible assets 7.25M 6.41M 0.02M -
Short term investments - - - -
Net receivables 1.25M 2.13M 0.15M -
Long term debt 0.02M - 0.04M 0.00000M
Inventory 0.02M - - -
Accounts payable 0.54M 0.04M 0.26M 0.00136M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income - - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 0.22M - - -
Deferred long term asset charges - - - -
Non current assets total 6.92M - 3.11M 2.49M
Capital lease obligations 4.60M - 2.87M 2.54M
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2020-08-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2020-08-31
Investments 1.39M -1.24200M -0.69703M -0.01800M
Change to liabilities 0.35M -0.01394M 0.67M 0.00000M
Total cashflows from investing activities 1.39M 0.29M -0.69703M -0.69703M
Net borrowings -1.51900M -1.51900M 0.05M 0.05M
Total cash from financing activities 5.95M 7.91M 1.07M 1.07M
Change to operating activities - - - -
Net income -17.41100M -4.78300M -1.05979M 0.00000M
Change in cash 1.24M 3.52M 0.30M 0.30M
Begin period cash flow 3.82M 0.30M 0.00149M -
End period cash flow 5.06M 3.82M 0.30M 0.00149M
Total cash from operating activities -6.10000M -3.14800M -0.07757M -0.07757M
Issuance of capital stock 7.49M 0.39M 1.02M -
Depreciation 0.47M 0.32M 0.16M 0.16M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory -0.01800M -0.01800M -0.01800M -0.01800M
Change to account receivables -0.98500M -1.98890M -0.18692M -0.18692M
Sale purchase of stock - - - -
Other cashflows from financing activities -0.03200M 7.70M 0.05M -0.02250M
Change to netincome 11.49M -0.22562M 0.34M 0.34M
Capital expenditures 2.09M 0.54M 0.71M 0.71M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital -0.64800M 0.02M 0.48M -
Stock based compensation 7.31M 0.00000M - -
Other non cash items 4.18M 1.29M 0.34M -
Free cash flow -8.18600M -3.69000M -0.78582M -

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CEL
Celadon Pharmaceuticals PLC		 - -% - - - 3516.20 21.15 3683.99 -16.9175
HLN
Haleon PLC		 -4.1 1.21% 334.00 20.24 18.94 2.95 2.02 3.68 14.19
HIK
Hikma Pharmaceuticals PLC		 19.00 1.30% 1482.00 9.73 9.03 0.85 1.45 1.53 6.07
HCM
HUTCHMED China Ltd		 1.25 0.74% 169.25 5.38 19.30 3.37 2.02 2.25 2.40
AGY
Allergy Therapeutics		 0.10 1.19% 8.50 - 106.38 11.72 159.47 12.12 -4.1496

Reports Covered

Stock Research & News

View All

Profile

Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.

Celadon Pharmaceuticals PLC

32-33 Cowcross Street, London, United Kingdom, EC1M 6DF

Key Executives

Name Title Year Born
Mr. James Short CEO & Director NA
Ms. Kathleen Joy Long BCOMM, CA CFO & Director 1978

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions